Vertex Pharmaceuticals Incorporated (VRTX)

Healthcare | Biotechnology
Latest reporting period: 2026-03-31

Latest Quarter

2026-03-31

Revenue

$3.0B

Net Income

$1.0B

Operating Margin

38.1%

Free Cash Flow

$3.2B

Debt / Assets

28.6%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Vertex Pharmaceuticals Incorporated (VRTX).
Income Statement (Quarterly) 2026-03-31 2025-03-31 2024-12-31 2024-09-30
Revenue 2,986,900,000 2,770,200,000 2,912,000,000 2,771,900,000
Cost of Revenue 392,800,000 363,000,000 423,400,000 392,600,000
Gross Profit 2,594,100,000 2,407,200,000 2,488,600,000 2,379,300,000
Operating Expenses
R&D Expenses 0 0 0 0
SG&A Expenses 493,700,000 396,400,000 377,600,000 371,800,000
Operating Expenses 1,456,000,000 1,777,100,000 1,376,300,000 1,263,000,000
Operating Income 1,138,100,000 630,100,000 1,026,000,000 1,116,300,000
Interest Expense 0 3,000,000 2,800,000 7,500,000
Income Before Tax 1,252,900,000 730,400,000 1,136,500,000 1,224,100,000
Income Tax Expense 221,500,000 84,100,000 223,500,000 178,700,000
Net Income 1,031,400,000 646,300,000 913,000,000 1,045,400,000
Per Share
EPS 4.06 2.52 3.55 4.05
EPS Diluted 0.00 0.00 0.00 0.00